Trial Profile
A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Belizatinib (Primary)
- Indications Lymphoma; Neuroectodermal tumours; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors TESARO
- 20 Jun 2019 Results assessing safety, tolerability and pharmacokinetic profile of TSR-011 in relapsed or refractory metastatic cancer published in the British Journal of Cancer
- 25 Mar 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.